VolitionRx Details DETECSEPS Program Launch in France

VolitionRx Limited has shared additional details and a video concerning the launch of the government-funded DETECSEPS Consortium program in France. The company is participating in this multi-national epigenetics initiative focused on improving cancer detection methods.

The DETECSEPS program, backed by French government funding, intends to enhance early cancer detection through the analysis of epigenetic markers in blood samples. VolitionRx contributes its proprietary technology for detecting DNA methylation patterns associated with cancer.

This launch in France represents a step forward in the country's cancer research and diagnostic development landscape. The consortium plans to gather clinical data and validate new diagnostic tools across a wider population. Specifics on the funding amount or program timeline were not disclosed.

VolitionRx anticipates that findings from the DETECSEPS program could support the future development and commercialization of its own blood-based cancer tests. The company is listed on the NYSE American exchange under the ticker VNRX.